Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis

Inclusion Criteria: * Subject has had stable moderate to severe plaque psoriasis for at least 6 months * Subject has involved BSA ≥ 10% and PASI ≥ 10 at screening and at baseline. * Subject is a candidate for systemic therapy or phototherapy in the opinion of the investigator Exclusion Criteria: * Subject has active guttate, erythrodermic, or pustular psoriasis at the time of the screening visit. * Subject has evidence of skin conditions at the time of the screening visit (eg, eczema) that would interfere with evaluations of the effect of etanercept and/orclobetasol propionate foam on psoriasis. * Subject diagnosed with medication-induced or medication exacerbated psoriasis * Subject has any active Common Toxicity Criteria (CTC) grade 2 or higher infection * Subject has a significant concurrent medical condition or laboratory abnormalities as defined in the study protocol. * Subject has used any of the following therapies within 14 days of the first dose: UVB therapy or topical psoriasis therapies other than Class I or II topical steroids. * Subject has used any of the following therapies within 28 days of the first dose: Class I or II topical steriods, UVA therapy (with or without psoralen), or systemic psoriasis therapies * Subject has used one or more biologic therapies (other than interleukin (IL)12/IL23 inhibitors) within 3 months of the first dose * Subject has used an IL-12/IL-23 inhibitor within 6 months of the first dose of etanercept * Subject has ever used efalizumab (Raptiva®).